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Abstract
Background—Maintaining a gluten free diet (GFD) without an underlying diagnosis of celiac 
disease has enjoyed widespread acceptance in the USA.
Methods—We performed a cross-sectional study utilizing a GFD questionnaire in 1647 patients 
with inflammatory bowel diseases (IBD) participating in the CCFA Partners longitudinal, Internet-
based cohort.
Results—A diagnosis of celiac disease (CD) and non-celiac gluten sensitivity (NCGS) were 
reported by 10 (0.6%) and 81 (4.9%) respondents, respectively. Three hundred fourteen (19.1%) 
participants reported having previously tried a GFD and 135 (8.2%) reported current use of GFD. 
Overall 65.6% of all patients, who attempted a GFD described an improvement of their GI-
symptoms and 38.3% reported fewer or less severe IBD flares. In patients currently attempting a 
GFD, excellent adherence was associated with significant improvement of fatigue (p<0.03).
Conclusion—In this large group of patients with IBD, a substantial number had attempted a 
GFD, of whom the majority had some form of improvement in GI-symptoms. Testing a GFD in 
clinical practice in patients with significant intestinal symptoms, which are not solely explained by 
the degree of intestinal inflammation, has the potential to be a safe and highly efficient therapeutic 
approach. Further prospective studies into mechanisms of gluten sensitivity in IBD are warranted.
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INTRODUCTION
The pathogenesis of inflammatory bowel diseases (IBD), including Crohn’s disease (CD) 
and ulcerative colitis (UC), has only been partly elucidated. The most likely factors involved 
in promoting the onset and continuation of intestinal inflammation in IBD are an individual 
genetic predisposition, influence of the host microbiome and still largely undefined 
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environmental triggers. Diet has long been implicated as one of the contributing factors for 
disease flare-ups of IBD.1, 2 Accordingly, an elemental diet is a well-established treatment 
modality in children with IBD. Nevertheless, up to now, clinical trials investigating various 
diets have failed to yield significant clinical improvement in adult IBD.3, 4
Adoption of a gluten free diet (GFD) without an underlying diagnosis of celiac disease has 
experienced a rapid and widespread increase in the US in recent years. Currently at least 
0.5% of the US population follow a GFD without having a confirmed diagnosis of celiac 
disease.5 Even in the absence of celiac disease, gluten is thought to be associated with 
bloating, diarrhea, abdominal pain, fatigue and nausea, leading to the definition of a new 
entity designated as non-celiac gluten sensitivity (NCGS).6 Many of the symptoms 
associated with gluten exposure in the general population are also common in IBD patients 
and may partially be responsible for a diminished quality of life.
A better understanding of patient-reported outcomes is essential to developing new insights 
into the effectiveness of IBD therapies. Investigating the effects of diet on disease course 
could open potentially new research avenues.
With this study we aimed to determine the experience with a GFD in patients with IBD. 
Specifically we evaluated the current prevalence of self-reported celiac disease, NCGS and 
use of GFD, symptomatic improvement while being on GFD and the degree of adherence to 
a GFD in a cross-sectional study within the CCFA Partners cohort.
METHODS
CCFA Partners is an ongoing Internet-based cohort study of patients with IBD7. Participants 
complete a baseline survey and follow-up surveys occur every 6 months. As part of this 
cohort, we administered a 12-question survey on GFD from July 2013 through August 2013. 
Participants were asked if they 1) were ever on a GFD and if yes if they were still on a GFD, 
2) had been diagnosed with celiac disease or gluten sensitivity by a health care provider, 3) 
if GFD improved each of the following symptoms: bloating, diarrhea, abdominal pain, 
fatigue, nausea 4) if GFD led to less severe or fewer flares of their IBD and 5) if while 
following a GFD fewer medications were needed to control disease activity. Respondents, 
who still were on a GFD at the time of the survey, were asked to complete a validated seven-
item GFD adherence survey.8
Statistical analyses
Descriptive statistics were used to characterize the population, including proportions and 
95% confidence intervals, medians and interquartile ranges, and means and standard 
deviations (SD) as appropriate. Bivariate statistics were used to compare reduction in flares 
by IBD subtype (CD versus UC) and by other factors. These statistics included Pearson's 
chi-square test statistic, Fisher's exact, Wilcoxon rank sum, and Student's t-test as 
appropriate. STATA version 10.0 (College Station, TX) was used for all analyses and p < 
0.05 was considered statistically significant. The Institutional Review Board at the 
University of North Carolina at Chapel Hill approved the study protocol.
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A total of 1647 patients, who completed both a baseline survey and the specific GFD 
questionnaire, were included in the study. Ten (0.6%) and 81 (4.9%) patients had been 
diagnosed with celiac disease and gluten sensitivity by their health care provider, 
respectively. Three hundred fourteen (19.1%) participants reported ever having tried a GFD 
and 135 (8.2%) reported current use of GFD. No differences were found between the GFD 
and non-GFD groups with regard to disease type, duration of disease, concomitant 
medication, educational status and other baseline characteristics (table 1). In a subanalysis, 
clinical base line characteristics of individuals who completed the GFD questionnaire were 
compared to individuals within the CCFA Partners cohort who were not asked to complete a 
GFD questionnaire. There were no clinical significant differences in disease type or baseline 
characteristics between both groups (data not shown).
Improvement of symptoms on a GFD
Of the 314 patients, who have ever followed or were still following a GFD, 206 (65.6%) 
reported that they experienced an improvement of at least one specific clinical symptom 
which has been associated with gluten exposure (see figure 1). Furthermore 38.3% also 
recounted fewer and less severe flares while being on a GFD and 23.6% stated that they 
required fewer medications to control the disease. There were no significant differences 
pertaining to baseline characteristics between patients with or without improvement of 
clinical symptoms on a GFD (data not shown).
Adherence to GFD and correlation with symptom improvement
In those patients who were still following a gluten free diet (n=135), adherence was found to 
be excellent in 41.5%, average in 34.1%, and fair/poor in 24.4%. Excellent adherence to a 
GFD was associated with reduced fatigue, as compared to fair/poor adherence (p<0.03). 
Adherence was not associated with significant differences in other clinical symptoms.
DISCUSSION
This is the largest survey analyzing patient-reported data about the prevalence of a gluten 
free diet in a Western IBD population. In this Internet based cohort nearly 20% of all 
patients reported having tried a GFD and 8% were currently attempting a GFD. This is a 
significantly higher percentage than the current GFD prevalence of 0.5% among individuals 
without celiac disease in the USA.5 More than half of the patients reported symptom 
improvement and nearly 40% fewer flare-ups of IBD while being on a GFD. This 
observation suggests that in a subgroup of IBD patients, gluten may cause intestinal 
(diarrhea, bloating, abdominal pain) and extraintestinal (fatigue, nausea) symptoms. Similar 
effects of a GFD have been described in patients with irritable bowel syndrome (IBS) 
indicating a potential trigger effect of gluten containing foods in gluten susceptible 
patients.9–11
NCGS is defined by the exclusion of celiac disease including negative celiac serologies 
and/or normal intestinal architecture and negative immunoglobulin (Ig)E-mediated allergy 
tests to wheat. Additionally, to meet criteria for NCGS, the clinical symptomatology of IBS 
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type of symptoms has to improve after gluten withdrawal and worsen after the ingestion of 
gluten. A specific reaction to gluten in patients with NCGS is currently debated.12 
Biesiekierski et al recently showed that gluten by itself might be not the culprit for the IBS 
type symptoms in patients with previously diagnosed NCGS, but rather the intake of low-
fermentable, poorly absorbed, short-chain carbohydrates (fermentable, oligo-, di-, 
monosaccharides, and polyols; FODMAPs) may be responsible for these effects.13 Also, 
gluten does not elicit an inflammatory response in the duodenum in patients with NCGS.14 
The diagnosis of NCGS was reported by nearly 5% of the respondents in our survey. Thus 
far studies in patients with IBD investigating inflammatory responses to gluten in duodenal 
or colonic biopsies have not been performed. Theoretically gluten could create a pro-
inflammatory environment in the intestine, leading to more frequent disease flares and the 
need for more intensified therapies, similar to patients with IBD and concurrent celiac 
disease.15 However, we cannot exclude that a GFD leads to a significant reduction of dietary 
FODMAPs, which as shown by Biesiekierski et al., leads to an improvement of the GI 
symptoms of the patients.13 Of note, an exploratory study has demonstrated that dietary 
reduction of FODMAPs leads to significant amelioration of symptoms including abdominal 
pain, bloating, gas and diarrhea in patients with IBD.16
Those patients maintaining a GFD at the time period of the survey were asked to fill out a 
recently validated 7-item Celiac Dietary Adherence Test.8 The additive scores of this test 
reflect the adherence to a GFD and correlate highly with a standardized dietician evaluation 
and appear to outperform serological testing. However, the test does not quantify the amount 
of gluten intake, but rather points to the likelihood of gluten contamination. More than 40% 
of the respondents were strictly maintaining to a GFD, whereas roughly 25% of the patients 
were found to be fair or poorly adherent. Intriguingly, of all clinical symptoms, only fatigue 
improved significantly with good adherence. Fatigue in the absence of iron deficiency 
anemia is a leading symptom in many patients with IBD.17 It is possible that fatigue 
conversely influenced adherence in our cohort, but coincidently, the worsening of fatigue 
was also the most significant finding in a gluten challenge study conducted in patients with 
NCGS.9
The class II MHC haplotype HLA-DQ2 and HLA-DQ8 are present in almost all CD patients 
and interestingly can be also found in 50% of patients, who are improving on a gluten free 
diet, which is higher than can be expected in the general population.6 Studies in patients 
with irritable bowel syndrome with predominantly diarrhea (IBS-D) have also shown, that 
carrier of HLA-DQ2 respond favorably to a gluten free diet. In fact in 60% of the patients 
with IBS-D HLA-DQ2 positivity, but no signs of overt celiac disease (negative TTG 
antibodies and no signs of active celiac disease on biopsies obtained in the duodenum), 
symptoms such as diarrhea and bloating improved on a 6 months gluten free diet compared 
to only 12% in patients without HLA-DQ2 positivity.18 As it is speculated in patients with 
NCGS, gluten might have a direct impact on intestinal barrier function and the mucosal 
immune system in IBD patients with the HLA-DQ-2 or DQ 8 genotype.19 In a recent study 
by Vazquez-Roque et al the small intestinal permeability was significantly increased in IBS-
D patients with HLA-DQ2 or 8 positivity on a gluten containing diet (GCD), but this was 
not the case in HLA-DQ 2 and 8 negative patients.11 Also RNA expressions of several 
proteins associated with the epithelial barrier in the in colonic mucosa (zonula occludens-1, 
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occludin and claudin) were generally lower in participants on a GCD compared to 
participants on a GFD. However, diet-associated changes of RNA expression reached only 
statistical significance in study participants, who were found to have a HLA-DQ 2 or 8 
positive status. HLA-DQ2 or DQ8 is not found in higher frequencies in IBD patients, but it 
would be fascinating to evaluate the associations of these haplotypes with the response to a 
gluten free diet in IBD patients in prospective studies.20 Moreover the degree of intestinal 
inflammation in non-celiac IBD patients could be influenced by the recently identified non-
gluten α-amylase / tryptase inhibitors (ATIs), which can be found in wheat and related 
cereals. These ATI are strong activators of the innate immune response via the Toll-like 
receptor 4, leading to the upregulation of pro-inflammatory cytokines in vitro and in vivo.21
Patient-reported data based from the CCFA partners cohort have several limitations as 
outlined recently.22 CCFA-Partners is a volunteer sample of patients and thus the above-
described findings may not reflect similar diet habits in all IBD patients. To address the 
possibility of selection bias within the sample completing the GFD questionnaire, we 
compared the characteristics of those who completed the questionnaire to those of the CCFA 
Partners cohort in general and found no clinical significant differences. Since the study was 
based on a single questionnaire without collecting blood samples, we did not rule out occult 
celiac disease with serologic tissue-transglutaminase testing neither could we determine the 
HLA DQ2 or DQ 8 status. Previous studies have shown that the prevalence of celiac disease 
in patients with IBD is comparable to the prevalence in the non-IBD population.15, 23 The 
finding that 0.6% of patients reported to be diagnosed with celiac disease is comparable to 
the currently reported 0.7% prevalence of celiac disease (including diagnosed and 
undiagnosed cases) in the United States.24 Currently the majority of celiac disease patients 
in the USA are undiagnosed, but since IBD patients suffer from similar GI-symptoms as 
many celiac disease patients, it is very likely that in the setting of the diagnostic work-up for 
IBD, concurrent celiac disease is diagnosed either by serologic testing or by endoscopy.
In conclusion, the high prevalence of a GFD in the CCFA Partners cohort strongly suggests 
a potential role of this diet in the adjunctive therapeutic management of subgroups of IBD 
patients. Testing GFD in clinical practice in patients with significant intestinal symptoms, 
which are not solely explained by the degree of intestinal inflammation, has the potential to 
be a safe and highly efficient therapeutic approach following appropriate testing for celiac 
disease. Further research into investigating possible mechanisms of gluten-mediated 
worsening of intestinal inflammation in susceptible IBD patients is also warranted.
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Reported symptom improvements in IBD patients attempting a GFD (n=314)
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Table 1
Baseline characteristics of the inflammatory bowel disease population in CCFA Partners, stratified by ever or 










Age, years 46.5 (15.4) 46.2 (15.4) 0.88
Sex
Female (%) 74 74 0.99
Type of IBD (%)
Crohn’s disease 61 63 0.62
Ulcerative/indeterminate colitis 39 37
Duration of disease years 17.4 (13.4) 16.5 (12.8) 0.25
Ostomy (% yes) 6.9 7.8 0.60
Medications (%)
  5-ASA 74.5 71.4 0.27
  Corticosteroids 27.7 23.6 0.12
  Immunomodulators 45.9 47.0 0.70
  Biologic anti-TNF 55.4 54.7 0.82
Education (%)
  High school or less 7.4 6.4 0.51
  College + 92.6 93.6
Disease activity
  sCDAI** 148.8 (97.3) 142.5 (90.0) 0.35
  SCCAI# 3.2 (2.5) 3.1 (2.6) 0.73
Quality of life SIBDQ^ 5.0 (1.2) 5.1 (1.1) 0.70
BMI 25.7 (6.7) 26.0 (7.2) 0.60
*
by wilcoxon rank sum, t-test, chi square or fisher’s exact as appropriate
**
short Crohn’s disease activity index
#
simple clinical colitis activity index
^
short inflammatory bowel disease questionnaire
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